Suyan Li

Suyan Li has worked in the scientific field since 2011. Suyan began as a Research Fellow at McLean Hospital, where they identified expression of serine racemase (SR) and synthetization of D-serine in primary astrocytes, established an AD mouse model, isolated and cultured primary neuronal, astrocytes, and microglia cells, and trained laboratory members. In 2018, they joined Eisai US as a Senior Researcher, where they focused on pre-clinical study and early drug development of Alzheimer disease, assessed/characterized biomarker in mouse and human plasma/serum/urine, successfully optimized several IHC/IF antibodies, developed FISH/CISH protocols, performed digital morphometric analysis, presented study results, authored study reports, and more. In 2019, they became a Scientist and then a Principal associate scientist at Sigilon Therapeutics, Inc. In 2022, they will become a Senior Scientist at Garuda Therapeutics.

Suyan Li has a Doctor of Biology degree in Neuroscience and Molecular Biology from the Institute of Radiation Medicine in Beijing, China.